GlassScriptPhysician profile
Irum M Noor
NPI 1811309933
$18,356.12
in general payments reported to CMS, 2019-2025
33 companies · $11K in 2025
The $11K reported for 2025 was more than what 88% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $500 · 2021: $1,093 · 2022: $1,854 · 2023: $2,203 · 2024: $1,884 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $7,550 · Food and Beverage: $5,366 · Travel and Lodging: $1,730 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $7,550.00 |
| Food and Beverage | $5,366.44 |
| Travel and Lodging | $1,730.34 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $9,583.76 | 2020-2025 | Odactra, Ragwitek, Grastek |
| Regeneron Healthcare Solutions, INC. | $2,388.59 | 2020-2025 | Dupixent |
| Genzyme Corporation | $2,031.88 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,099.63 | 2021-2025 | Nucala |
| Optinose US, INC. | $597.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $326.08 | 2021-2025 | Cuvitru, Elaprase |
| Kaleo, INC. | $270.26 | 2020-2024 | Auvi-Q |
| Amgen INC. | $256.98 | 2022-2024 | Tezspire |
| Incyte Corporation | $246.73 | 2021-2023 | Opzelura |
| Astrazeneca Pharmaceuticals LP | $209.92 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Ars Pharmaceuticals Operations, INC. | $184.75 | 2025 | Neffy |
| Pfizer INC. | $106.36 | 2022-2024 | |
| Grifols USA, LLC | $101.04 | 2022-2025 | Xembify |
| Dermavant Sciences, INC. | $72.84 | 2023 | Vtama |
| Medtronic, INC. | $72.29 | 2024 | Propel, Nuvent |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $70.36 | 2024-2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $65.37 | 2021 | |
| Aimmune Therapeutics, INC. | $61.24 | 2022 | |
| Hikma Pharmaceuticals USA | $59.39 | 2023-2025 | Ryaltris |
| Csl Behring | $58.20 | 2019-2024 | Haegarda |
| Genentech USA, INC. | $56.76 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $53.55 | 2019-2025 | |
| Inspire Medical Systems, INC. | $45.76 | 2025 | Inspire |
| Phadia US INC. | $41.81 | 2023-2024 | Immunocap |
| Abbvie INC. | $41.72 | 2022-2023 | |
| Epi Health, LLC | $40.00 | 2022 | |
| Octapharma USA, INC. | $38.78 | 2022 | |
| Stryker Corporation | $37.44 | 2024-2025 | Audion Et Dilation System, Scopis Ent |
| Aytu Biopharma, INC. | $36.95 | 2023-2025 | |
| Acclarent, INC | $34.78 | 2020 | |
| Tersera Therapeutics LLC | $26.88 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.37 | 2020 | |
| Neos Therapeutics, LP | $18.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irum Noor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.